Eli Lilly has announced that some Medicare enrollees using its GLP-1 medications for weight loss and obesity management might face out-of-pocket expenses that exceed the new...
Hims & Hers Health has announced a remarkable revenue growth of nearly 50% year over year for the third quarter of 2025, reaching approximately $600 million....
Health Canada is currently reviewing nine submissions for generic versions of popular obesity medications, potentially paving the way for lower prices this summer. The focus is...
McKesson Corporation, one of the leading pharmaceutical distribution companies in the United States, is projecting a significant slowdown in growth for the fiscal year 2026. Following...
Recent research from the University of Utah has unveiled a promising method for enhancing glucagon-like peptide-1 (GLP-1) agonists, potentially paving the way for a new generation...
